Clinical Implications of Thrombocytopenia at Cardiogenic Shock Presentation: Data from a Multicenter Registry by 고영국 et al.
851www.eymj.org
INTRODUCTION
Thrombocytopenia (platelet count <150×103/μL) is common 
in critically ill patients. Complement activation, extracellular 
histones, dilution, hemophagocytosis, and thrombin-mediat-
ed platelet activation are well-known key pathophysiologies 
underlying thrombocytopenia in these patients.1 Since throm-
bocytopenia can contraindicate some invasive procedures or 
necessitate specific therapies, such as platelet transfusion,2,3 
its clinical implication is fairly evident in critically ill patients.4-7
In particular, thrombocytopenia is of great concern in pa-
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tients with severe cardiac diseases,8 as anticoagulants, anti-
platelet agents, or invasive procedures including percutaneous 
coronary intervention (PCI) and extracorporeal membrane ox-
ygenation (ECMO) implantation are a vital part of treatment in 
these patients.9-11 Actually, there have been several previous 
studies investigating the prognostic role of thrombocytopenia 
in patients with acute coronary syndromes.12-14
However, the prognostic value of thrombocytopenia has not 
been sufficiently evaluated in patients with cardiogenic shock 
(CS). Although there have been several biomarkers shown to 
be associated with prognosis in patients with CS, such as glu-
cose, albumin, and lactate,15-18 conflicting results have been 
reported regarding platelet count as a prognostic biomark-
er.8,12,13 Consequently, well-known CS risk-scoring systems, in-
cluding CardShock score or IABP-SHOCK II risk score, do not 
incorporate platelet counts or thrombocytopenia.19,20 
Therefore, this study was conducted to identify the preva-
lence and prognostic significance of thrombocytopenia in pa-
tients with CS with the aim of providing a new perspective on 
the risk stratification of patients with CS.
MATERIALS AND METHODS
Study population
The SMart Angioplasty Research Team: A Multi-center, open, 
REtrospective and prospective observational Study to investi-
gate Clinical oUtcomes and Efficacy of left ventricular-assist 
devices for Korean patients with cardiogenic shock (SMART 
RESCUE) study is a Korean retrospective and prospective, ob-
servational, multicenter registry for evaluating the clinical out-
comes of patients aged ≥19 years with CS, recruited between 
January 2014 and December 2018 from 12 Korean tertiary care 
centers (ClinicalTrials.gov NCT02985008). The criteria for CS 
included systolic blood pressure <90 mm Hg for 30 minutes de-
spite adequate fluid resuscitation or the need for inotropes or 
vasopressors to maintain systolic blood pressure ≥90 mm Hg, 
clinical signs of peripheral hypoperfusion (any of the following: 
altered mental status, cold extremities, urine output <0.5 mL/
kg/h, serum lactate ≥2.0 mmol/L), and signs of acute pulmo-
nary edema. Exclusion criteria included non-cardiac origin 
shock, shock accompanied by out-of-hospital cardiac arrest, 
patients allergic to heparin, or refusal to receive aggressive 
medical therapy.
Among 1247 CS patients in the registry, 20 patients with 
missing platelet counts and 25 patients with incomplete fol-
low-up information were excluded. Consequently, a total of 
1202 patients with CS were included in our analysis (Fig. 1). Writ-
ten informed consent was obtained from the patient or the 
next of kin upon admission, and the Institutional Ethics Com-
mittees of each participating center approved this study (ap-
proval no. 4-2017-0880).
Data collection and definition of clinical outcomes
Participants’ data on the demographics, anthropometric indi-
ces, and underlying medical conditions were collected at base-
line. Hemodynamic, laboratory, and echocardiographic pa-
rameters were measured at shock presentation to quantitatively 
assess the severity of patients’ clinical status. In addition, the 
doses of required inotropes and/or vasopressors were mea-
sured and transformed into vasoactive inotropic scores to stan-
dardize the doses of different inotropes and vasopressors.21 Es-
timated glomerular filtration rate (eGFR) was calculated using 
the Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation.22 
During the course of hospitalization, data were collected on 
survival and complications, such as gastrointestinal (GI) bleed-
ing, sepsis, and stroke. Patient management strategies, includ-
ing the decision for intra-aortic balloon pump and/or ECMO, 
were based on the clinical protocols of each center. All-cause 
30-day mortality was assessed as a measure of clinical out-
come, and the length of stay in the intensive care unit (ICU) 
and hospital were assessed among patients who survived to 
discharge.
Statistical analysis
Continuous variables are expressed as mean±standard devia-
tion for normally distributed variables or median [interquartile 
range] for variables with skewed distribution. The Student’s t-
test was used for between-group comparison of continuous 
variables. All categorical variables are expressed as number 
(proportion) and compared using either the chi-square test or 
Fisher’s exact test.
The cumulative survival of participants according to the 
presence or absence of thrombocytopenia was estimated with 
the Kaplan-Meier method, and compared by the log-rank test. 
To identify and adjust for potential confounders, univariable 
Cox proportional hazards regression analyses were performed, 
SMART-RESCUE registry








Fig. 1. Flowchart of the study. F/U,  follow-up.
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followed by multivariable analysis. Covariates were selected 
based on their heterogeneity between groups, statistical sig-
nificance on univariable analyses, or previously known rela-
tionship with major clinical outcomes in patients with CS.15,17,19,20 
Moreover, to examine any potential nonlinear relationship be-
tween platelet count and risk for 30-day mortality, restricted 
cubic spline plot was fitted with Cox proportional hazard model 
with the same covariates as above.
In addition, subgroup analysis was performed to identify 
any effect modification by demographic/clinical factors after 
stratifying participants according to age (<65 years, ≥65 years), 
sex, body mass index (<25 kg/m2, ≥25 kg/m2), history of coro-
nary artery occlusive disease, systolic blood pressure (<60, 
60–69, 70–79, and ≥80 mm Hg), left ventricular (LV) ejection 
fraction (≥40%, <40%), lactate level (≤5 mmol/L, >5 mmol/L), 
and cause of shock [acute myocardial infarction (AMI), non-
Table 1. Baseline Characteristics at Cardiogenic Shock Presentation
With thrombocytopenia (n=244) Without thrombocytopenia (n=958) p-value
Age (yr) 66±14 66±14 0.732
Men 166 (68.0) 660 (68.9) 0.796
Body mass index (kg/m2) 23.0±3.5 23.5±3.5 0.035
Cardiovascular risk factors
Current smoking 57 (23.4) 287 (30.0) 0.042
Hypertension 127 (52.0) 515 (53.8) 0.633
Diabetes 89 (36.5) 342 (35.7) 0.821
Dyslipidemia 54 (22.1) 271 (28.3) 0.053
History of CAOD 49 (20.1) 177 (18.5) 0.630
History of PAOD 11 (4.5) 39 (4.1) 0.760
History of CVA 25 (10.2) 89 (9.3) 0.649
History of CKD 29 (11.9) 89 (9.3) 0.224
Systolic BP (mm Hg) 70 [60–80] 77 [63–86] 0.001
Diastolic BP (mm Hg) 45 [37–54] 50 [40–59] 0.001
Mean BP (mm Hg) 53 [44–62] 58 [48–67] <0.001
Heart rate (beats per minute) 88±31 86±31 0.289
LV ejection fraction <40% 107/177 (60.5) 351/607 (57.8) 0.591
Platelet count (103/µL) 106±32 238±68 <0.001
Hemoglobin (g/dL) 11.6±3.0 12.9±2.4 <0.001
Total bilirubin (mg/dL) 0.9 [0.5–1.9] 0.6 [0.4–0.9] <0.001
Aspartate aminotransferase (IU/L) 10.0 [3.9–31.0] 4.6 [2.7–14.0] 0.004
Alanine aminotransferase (IU/L) 5.2 [2.3–16.8] 3.1 [1.8–6.7] 0.001
Estimated GFR (mL/min/1.73 m2) 54.1±28.3 61.3±27.3 <0.001
Glucose (mg/dL) 182 [134–261] 190 [141–278] 0.503
Creatine kinase-MB (µg/dL) 5.3 [1.0–21.1] 10.7 [2.0–28.3] 0.345
Troponin-I (ng/mL) 5.3 [0.4–42.8] 7.1 [0.6–50.0] 0.027
Lactate >5 mmol/L 115/189 (60.8) 328/687 (47.7) 0.002
Central venous oxygen saturation (%) 64.6±23.1 64.8±21.2 0.961
Vasoactive inotropic score* 33.0 [7.0–100.0] 22.2 [10.0–73.2] 0.096
Cause of shock <0.001
Acute myocardial infarction 163 (66.8) 809 (84.4)
Dilated cardiomyopathy 28 (11.5) 46 (4.8)
Myocarditis 13 (5.3) 24 (2.5)
Valvular heart disease 8 (3.3) 10 (1.0)
Refractory VT/Vf 8 (3.3) 22 (2.3)
Pulmonary thromboembolism 8 (3.3) 15 (1.6)
Others 16 (6.6) 32 (3.3)
BP, blood pressure; CAOD, coronary artery occlusive disease; CKD, chronic kidney disease; CVA, cerebrovascular accident; GFR, glomerular filtration rate; LV, left 
ventricular; PAOD, peripheral artery occlusive disease; Vf, ventricular fibrillation; VT, ventricular tachycardia.
Results are shown as mean±standard deviation or median [interquartile range] for continuous variables and n (%) or n/total n (%) for categorical variables.
*Vasoactive inotropic score was calculated as dopamine dose (ug/kg/min)+dobutamine dose (ug/kg/min)+100∙epinephrine dose (ug/kg/min)+10∙milrinone dose 
(ug/kg/min)+10000∙vasopressin dose (U/kg/min)+100∙norepinephrine dose (ug/kg/min).
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AMI]. In addition, as the difference in revascularization could 
also be a potential confounder, the subgroup of patients with 
CS caused by AMI (AMI-CS) were further stratified according 
to the revascularization status, and an interaction analysis was 
performed. Proportional hazards assumption was tested with 
Schoenfeld residuals, and was found not to be violated. P-val-
ues <0.05 were considered statistically significant, and all sta-
tistical analyses were conducted using SAS version 9.4 (SAS 
Institute Inc., Cary, NC, USA) and R version 4.0.2 (R Founda-
tion for Statistical Computing, Vienna, Austria).
RESULTS
Baseline characteristics
Among 1202 patients (mean age, 66 years; 69% men) with CS, 
244 patients (20.3%) had thrombocytopenia at shock presen-
tation, whereas 958 (79.7%) patients had normal platelet counts. 
Age and sex distribution did not differ significantly between 
groups, but patients with thrombocytopenia showed lower 
body mass index compared to those without. In addition, 
smoking rate, blood pressure, hemoglobin, eGFR, and tropo-
nin-I levels were lower, while total bilirubin, liver enzymes, 
and proportion of patients with lactate >5 mmol/L were high-
er in patients with thrombocytopenia. Regarding the cause of 
shock, AMI was less frequent in patients with thrombocytope-
nia compared to patients without (Table 1).
In-hospital management and clinical outcomes 
Among patients within the AMI-CS subgroup, revasculariza-
tion was less frequently performed in thrombocytopenia group 
compared to normal platelet group (81.0% vs. 87.8%, p=0.001). 
However, mechanical circulatory support (intra-aortic balloon 
pump and/or ECMO), renal replacement therapy, and me-
chanical ventilation were more frequently required in patients 
with thrombocytopenia than in those without (all p <0.05). Re-
garding clinical outcomes, the incidence of ischemic and hem-
orrhagic stroke did not differ significantly between groups, 
while GI bleeding and sepsis occurred more frequently in pa-
tients with thrombocytopenia compared to those without (10.5% 
vs. 3.8%, p=0.009 and 8.3% vs. 2.6%, p=0.013, respectively). 
As a consequence, length of stay in ICU and hospital was 
longer in thrombocytopenia group (8 days vs. 4 days, p<0.001; 
17 days vs. 10 days, p<0.001, respectively) among 801 (66.6%) 
patients who survived to discharge (Table 2). Overall, 30-day 
all-cause mortality was 30.9%, and it was significantly higher 
in patients with thrombocytopenia than in those without [40.2% 
vs. 28.5%, hazard ratio (HR) 1.51, 95% confidence interval (CI) 
1.20–1.90, log-rank p<0.001) (Table 2 and Fig. 2).
In multivariable Cox model, every 103/µL decrease of plate-
let count was associated with a 0.2% higher risk of all-cause 
mortality at 30 days (HR 1.002, 95% CI 1.000–1.003, p=0.021). 
Other independent predictors of 30-day mortality were age, 
LV ejection fraction <40%, eGFR, creatine kinase-MB levels, 
lactate >5 mmol/L, vasoactive inotropic score, the need for 
mechanical circulatory support, and the need for mechanical 
Table 2. In-Hospital Management, Adverse Events, and Clinical Outcomes
With thrombocytopenia (n= 244) Without thrombocytopenia (n=958) p-value
In-hospital management
Revascularization (among AMI patients) 0.001
PCI 116/163 (71.2) 678/809 (83.8)
CABG 11/163 (6.7) 32/809 (4.0)
No revascularization 36/163 (22.1) 99/809 (12.2)
Mechanical circulatory support* 161 (66.0) 553 (57.7) 0.023
Renal replacement therapy 89 (36.5) 181 (18.9) <0.001
Mechanical ventilation 159 (65.2) 521 (54.4) 0.003
Adverse events during hospitalization
Gastrointestinal bleeding 14/133 (10.5) 13/340 (3.8) 0.009
Hemorrhagic stroke 3/133 (2.3) 15/340 (4.4) 0.404
Ischemic stroke 1/133 (0.8) 10/340 (2.9) 0.306
Sepsis 11/133 (8.3) 9/340 (2.6) 0.013
Clinical outcomes
Length of stay (days)†
Intensive care unit               8 [3–21]              4 [2–10] <0.001
Hospital            17 [8–40]            10 [5–21] <0.001
30-day mortality 98 (40.2) 273 (28.5) <0.001
AMI, acute myocardial infarction; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention.
Results are shown as mean±standard deviation or median [interquartile range] for continuous variables and n (%) or n/total n (%) for categorical variables.
*Mechanical circulatory support indicates implantation of intra-aortic balloon pump and/or extracorporeal membrane oxygenation, †Assessed in patients who 
survived to discharge.
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ventilation in our model (Table 3). In addition, restricted cu-
bic spline plot showed that the platelet count is negatively as-
sociated with the risk of 30-day mortality, even when it is with-
in its normal range (150–400∙103/µL). The inflection point was 
200∙103/µL in our cubic spline model (Fig. 3).
Subgroup analysis showed that the risks of 30-day mortality 
for every 103/µL decrease of platelet count were consistent 
across all the subgroups (Fig. 4). Furthermore, when confined 
only to the patients within AMI-CS subgroup, platelet count 
was still independently associated with all-cause mortality at 
30 days (HR 1.002, 95% CI 1.000–1.003, p=0.047; per 103/µL de-
crease), and the result did not differ by whether or not the pa-
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Fig. 2. Cumulative survival of the participants according to the presence or 
absence of thrombocytopenia. Cumulative survival was estimated using 
the Kaplan-Meier method, and compared by the log-rank test.
Table 3. Predictors of 30-Day Mortality
Variables
Univariable analysis Multivariable analysis
HR (95% CI) p-value HR (95% CI) p-value
Platelet count (per 103/µL decrease) 1.002 (1.001–1.003) 0.003 1.002 (1.000–1.003) 0.021
Age (yr) 1.022 (1.014–1.030) <0.001 1.018 (1.007–1.030) 0.001
Men 1.252 (1.011–1.549) 0.039 0.419
Body mass index (kg/m2) 0.982 (0.953–1.011) 0.222 0.742
Current smoking 0.708 (0.556–0.902) 0.005 0.132
Hypertension 1.239 (1.008–1.523) 0.041 0.906
Diabetes 1.228 (0.998–1.511) 0.053 0.331
History of CAOD 1.109 (0.862–1.427) 0.423 0.862
History of CVA 1.255 (0.910–1.730) 0.166 0.753
Systolic BP (mm Hg) 0.989 (0.984–0.995) <0.001 0.076
LV ejection fraction <40% 2.537 (1.849–3.483) <0.001 1.593 (1.116–2.274) 0.010
Hemoglobin (g/dL) 0.929 (0.893–0.966) <0.001 0.374
Total bilirubin (mg/dL) 0.992 (0.932–1.055) 0.797 0.982
eGFR (mL/min/1.73 m2) 0.985 (0.981–0.989) <0.001 0.992 (0.987–0.997) 0.002
Glucose (mg/dL) 1.002 (1.002–1.003) <0.001 0.076
Creatine kinase-MB (µg/dL) 1.004 (1.003–1.005) <0.001 1.002 (1.001–1.004) 0.003
Lactate >5 mmol/L 2.492 (1.952–3.181) <0.001 1.578 (1.194–2.085) 0.001
Vasoactive inotropic score 1.001 (1.001–1.002) <0.001 1.001 (1.001–1.001) <0.001
The need for mechanical circulatory support 2.913 (2.266–3.744) <0.001 1.682 (1.249–2.265) <0.001
The need for mechanical ventilation 6.094 (4.522–8.212) <0.001 3.536 (2.493–5.016) <0.001
BP, blood pressure; CAOD, coronary artery occlusive disease; CVA, cerebrovascular accident; eGFR, estimated glomerular filtration rate; LV, left ventricular.
Covariates were selected based on their heterogeneity between the study groups, statistical significance on univariable analyses, or previously known associa-
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Fig. 3. Non-linear relationship between the platelet count and 30-day mor-
tality. Restricted cubic spline plot shows hazard ratios with 95% confi-
dence intervals for 30-day mortality according to the platelet count. The 
plot was fitted with Cox proportional hazards model, adjusting for age, sex, 
body mass index, current smoking, hypertension, diabetes, history of cor-
onary artery occlusive disease, history of cerebrovascular accident, sys-
tolic blood pressure, left ventricular ejection fraction <40%, hemoglobin, 
total bilirubin, estimated glomerular filtration rate, glucose, creatine kinase-
MB, lactate >5 mmol/L, vasoactive inotropic score, the need for mechani-
cal circulatory support, and the need for mechanical ventilation.
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DISCUSSION
The principal findings of the study were as follows: 1) one-
fifth of the patients with CS had thrombocytopenia at shock 
presentation; 2) patients with thrombocytopenia at shock pre-
sentation showed lower blood pressure and hemoglobin lev-
el, worse hepatic and renal function, and higher lactate levels 
than patients without thrombocytopenia, suggesting worse 
clinical status; 3) patients with thrombocytopenia more fre-
quently required mechanical circulatory support, renal re-
placement therapy, or mechanical ventilation and experienced 
adverse events, including GI bleeding and sepsis, compared 
to patients without thrombocytopenia; and 4) ICU and hospi-
tal stays were longer and 30-day mortality was higher in pa-
tients with thrombocytopenia than in those without. In addi-
tion, the platelet count remained an independent predictor of 
30-day mortality after multivariable adjustment.
The proportion of patients with thrombocytopenia in our 
registry was 20%, which was relatively higher than that in pre-
vious studies.12-14,23 This finding could be explained by the dif-
ferences in baseline characteristics, as well as the higher sever-
ity of illness at shock presentation in our study’s participants. 
The detrimental effects of thrombocytopenia on clinical out-
comes is probably attributed to increased bleeding complica-
tions, as demonstrated by more frequent GI bleeding among 
patients with thrombocytopenia in our study. This finding is 
consistent with those of previous studies, in which thrombo-
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Fig. 4. Risk of all-cause mortality at 30 days for every 103/µL decrease of platelet count in each subgroup. The results were adjusted for age, sex, body mass 
index, current smoking, hypertension, diabetes, history of coronary artery occlusive disease, history of cerebrovascular accident, systolic blood pressure, 
LV ejection fraction <40%, hemoglobin, total bilirubin, estimated glomerular filtration rate, glucose, creatine kinase-MB, lactate, vasoactive inotropic 
score, the need for mechanical circulatory support, and the need for mechanical ventilation, except for the variable stratified on. AMI, acute myocardial 
infarction; BP, blood pressure; CAOD, coronary artery occlusive disease; LV, left ventricular.
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cation rates; however, these studies were not exclusively per-
formed on patients with CS.13,23 Although there are some 
contradictory results with regard to the association between 
thrombocytopenia and bleeding complications among pa-
tients with non-cardiac critical illnesses,24,25 this discrepancy 
could be explained by the higher frequency of invasive proce-
dures or more prevalent use of antithrombotic agents in pa-
tients with CS, all of which can potentiate the bleeding risk of 
thrombocytopenia.
In addition, the lower proportion of patients with AMI etiol-
ogy, implicating less reversibility by timely interventions, and 
the higher proportion of patients who did not undergo revas-
cularization of stenotic coronary arteries may also have con-
tributed as key factors to the poorer prognosis of patients with 
thrombocytopenia. Moreover, the perceived high risk of bleed-
ing in thrombocytopenia patients could have deterred inter-
ventionists from undertaking angioplasty and stent deploy-
ment for ambiguous coronary lesions. However, the association 
between platelet count and all-cause mortality at 30 days was 
consistent regardless of the revascularization status in AMI-CS 
patients in our analysis, implicating the possible presence of 
other additional mechanisms by which thrombocytopenia ex-
erts negative effects on clinical outcomes in these patients.
Higher rate of sepsis among patients with thrombocytopenia 
might be one of those mechanisms.7,26 As platelets are known 
to act as primary mediators of an immune system,27,28 immune 
dysregulation due to thrombocytopenia may increase the risk 
of sepsis,29,30 contributing to the higher risk of mortality in these 
patients. In addition, higher frequency of organ failure, includ-
ing renal and respiratory, in our study might also have been 
caused in part by dysregulated inflammatory response in 
thrombocytopenia patients, as platelets frequently serve as 
inflammatory mediators and participate in neurohormonal 
and inflammatory responses that play a key role in the patho-
physiology of CS.31 However, the detailed mechanism by which 
platelets contribute to the development and progression of CS 
is not well-known, and warrants further investigation.
This study has several distinguishing points. First, to the best 
of our knowledge, this is the first study to demonstrate the ef-
fect of thrombocytopenia on clinical outcomes in patients with 
CS. Moreover, we identified a dose-response relationship be-
tween platelet count and all-cause mortality at 30 days, which 
further validates the results of our study. Finally, various out-
come measures including 30-day mortality, length of stay in 
ICU and hospital, GI bleeding, stroke, and sepsis were analyzed, 
by which the reliability of the results could be enhanced.
However, our study also has some limitations. First, the 
causes of death were not identified, which made it difficult to 
analyze the association of thrombocytopenia with the direct 
causes of death in patients with CS. However, adverse events 
that might have significantly affected the hospital course were 
compared between groups, providing limited but meaningful 
information regarding the effect of thrombocytopenia on mor-
bidity. Second, changes in platelet counts during the hospital 
course were not considered in our study. Moreover, the poten-
tial differences in medications, especially antithrombotic agents, 
between the study groups were not assessed in our analysis. 
As the differences in the use of antiplatelet agents or anticoag-
ulants can influence the prognosis of patients with CS, further 
studies are required to identify whether thrombocytopenia is 
associated with poor outcome in CS regardless of antiplatelet 
or anticoagulant use. In addition, the time interval between 
symptom onset to hospital presentation or the door-to-balloon 
time among patients with AMI-CS were not considered in our 
analysis, which might also have influenced our results. Finally, 
only 30-day mortality was assessed in this study, and longer-
term prognosis of CS patients with thrombocytopenia needs 
to be further investigated.
In conclusion, one-fifth of the patients with CS had throm-
bocytopenia at shock presentation in our study, and these pa-
tients showed lower blood pressure, worse renal and hepatic 
function, and poorer systemic tissue perfusion compared to 
patients without thrombocytopenia. Consequently, patients 
with thrombocytopenia experienced more frequent adverse 
events during hospitalization, and showed higher 30-day mor-
tality than patients without thrombocytopenia. Moreover, low 
platelet count was an independent predictor of 30-day mortal-
ity in patients with CS in our study, along with age, LV ejection 
fraction <40%, eGFR, creatine kinase-MB, lactate >5 mmol/L, 
vasoactive inotropic score, the need for mechanical circulato-
ry support, and the need for mechanical ventilation. Further, 
large-scale studies are required to investigate the consistency 
of the findings of our study in the long run, as well as the po-
tential confounding effect of antiplatelet or anticoagulant use 
on the prognosis of patients with CS.
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